Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,248,243 | $1,828,292 | $1,037,418 | $844,287 |
| % Growth | 23% | 76.2% | 22.9% | – |
| Cost of Goods Sold | $323,370 | $310,406 | $168,817 | $140,144 |
| Gross Profit | $1,924,873 | $1,517,886 | $868,601 | $704,143 |
| % Margin | 85.6% | 83% | 83.7% | 83.4% |
| R&D Expenses | $1,126,232 | $1,004,415 | $883,015 | $792,156 |
| G&A Expenses | $975,526 | $795,646 | $770,658 | $620,639 |
| SG&A Expenses | $975,526 | $795,646 | $770,658 | $620,639 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2,050 |
| Operating Expenses | $2,101,758 | $1,800,061 | $1,653,673 | $1,412,795 |
| Operating Income | -$176,885 | -$282,175 | -$785,072 | -$708,652 |
| % Margin | -7.9% | -15.4% | -75.7% | -83.9% |
| Other Income/Exp. Net | -$200,490 | -$151,342 | -$341,921 | -$143,492 |
| Pre-Tax Income | -$377,375 | -$433,517 | -$1,126,993 | -$852,144 |
| Tax Expense | -$99,218 | $6,725 | $4,163 | $680 |
| Net Income | -$278,157 | -$440,242 | -$1,131,156 | -$852,824 |
| % Margin | -12.4% | -24.1% | -109% | -101% |
| EPS | -2.18 | -3.52 | -9.3 | -7.2 |
| % Growth | 38.1% | 62.2% | -29.2% | – |
| EPS Diluted | -2.18 | -3.52 | -9.3 | -7.2 |
| Weighted Avg Shares Out | 127,651 | 124,906 | 121,689 | 118,451 |
| Weighted Avg Shares Out Dil | 127,651 | 124,906 | 121,689 | 118,451 |
| Supplemental Information | – | – | – | – |
| Interest Income | $121,992 | $95,561 | $24,808 | $1,579 |
| Interest Expense | $141,858 | $121,221 | $155,968 | $143,021 |
| Depreciation & Amortization | $56,670 | $54,054 | $44,468 | $47,567 |
| EBITDA | -$178,847 | -$258,242 | -$926,557 | -$661,556 |
| % Margin | -8% | -14.1% | -89.3% | -78.4% |